Amgen Inc. AMGN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · amgen.com
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics, focusing on medicines to treat serious illnesses including cancer, cardiovascular disease, bone disease, and neurological disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is one of the world's largest biotechnology companies with a portfolio of marketed products including Enbrel, Otezla, Prolia, XGEVA, and Repatha.
Key ratios
FreeCashFlowOnSale TTM 0.22
FreeCashFlowOnSale 2025 0.22
FreeCashFlowOnSale 2024 0.31
FreeCashFlowOnSale 2023 0.26
NetIncomeMargin TTM 0.21
NetIncomeMargin 2025 0.21
NetIncomeMargin 2024 0.12
NetIncomeMargin 2023 0.24
ReturnOnAssets TTM 0.08
ReturnOnAssets 2025 0.08
ReturnOnAssets 2024 0.06
ReturnOnAssets 2023 0.08
ReturnOnEquity TTM 1.06
ReturnOnEquity 2025 1.06
ReturnOnEquity 2024 0.68
ReturnOnEquity 2023 1.36
Recent news
EU regulator backs revoking Amgen's right to sell rare-disease drug
2026-06-26 · Global Banking & Finance
Amgen Defends Rare Disease Drug in FDA Crosshairs
2026-06-12 · MedCity News
Amgen to Present New Data Across Rare Autoimmune and Inflammatory Diseases at EULAR 2026
2026-06-03 · PR Newswire